Biodesix announced that the employment of Chief Commercial Officer Kieran O’Kane ended on November 2, 2026. He is eligible for separation benefits under his Executive Severance and Change in Control Agreement based on a qualifying termination. The company operates in the healthcare diagnostics sector.
